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The Centre for the AIDS Programme of Research in South
Africa 004 (CAPRISA 004) study demonstrated that vagi-
nally applied tenofovir gel is a promising intervention for
protecting women from sexually acquiring human immuno-
deficiency virus (HIV). However, the potential for emergence
of tenofovir resistance remains a concern in women who
seroconvert while using the gel despite the lack of plasma
virus resistance as assessed by population sequencing during
the trial. We applied highly sensitive polymerase chain reac-
tion–based assays to screen for tenofovir resistance in plasma
and vaginal swab specimens. The absence of mutation detec-
tion suggested little immediate risk of tenofovir-resistant
HIV-1 emergence and forward transmission in settings in
which gel users are closely monitored for HIV seroconversion.
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Globally, women are disproportionately affected by human im-
munodeficiency virus (HIV) infection and the availability of
efficacious female-controlled products for preventing virus
acquisition is essential to alleviating this burden. In the wake
of several trials of barrier microbicides that demonstrated no
protection against HIV, vaginal microbicides containing antire-
troviral drugs have become leading candidates for the preven-
tion of HIV sexual transmission in women. The Centre for
the AIDS Programme of Research in South Africa 004 trial
(CAPRISA 004) assessed the efficacy of 1% tenofovir gel in sex-
ually active women and identified a 39% lower HIV incidence in
the tenofovir gel arm compared with the placebo arm, an effec-
tive incidence rate ratio of 0.61 (confidence interval, .4–.94;
P = .02) [1]. Subsequent examination of vaginal aspirates with
quantifiable tenofovir concentrations found that seroconversion
in the tenofovir gel arm was associated with a lower tenofovir
concentration geometric mean (634.85 ng/mL) than in women
who remained protected (7582.76 ng/mL; P = .09 [t test]).
As with any intervention involving antiretroviral drugs,
emergence of drug resistance is a concern. Trace concentrations
of tenofovir can be detected in vaginal aspirates up to 30 days
after gel application; thus, the long suboptimal tenofovir tail
may provide an environment for transmitted virus to develop
drug resistance. In the primary CAPRISA 004 data analysis
[1], bulk sequence genotyping of tenofovir gel breakthrough in-
fections identified no drug resistance in plasma virus several
months after seroconversion. However, there were limitations
to this resistance analysis. Foremost, the time since seroconver-
sion and, hence, drug exposure was approximately 5 months,
which may have been sufficiently long to allow for resistance
to decay below detection by population genotyping. Moreover,
topically applied drug remains concentrated in the vaginal com-
partment with little systemic exposure. Therefore, drug pressure
may not have been sufficient for resistance mutations to emerge
or become detectable in the peripheral circulation when exam-
ined by bulk sequencing.
In this study, we applied polymerase chain reaction (PCR)–
based mutation screening assays with improved sensitivity to
reexamine HIV seroconverters in the CAPRISA 004 trial for ev-
idence of tenofovir drug resistance in plasma virus that might
have emerged at levels below what could be detected by bulk se-
quence analysis. Moreover, we evaluated whether virus colocal-
ized with tenofovir gel in the vaginal compartment might result
in higher levels of the K65R resistance mutation than what was
observed for plasma. The combination of assays with improved
sensitivity for mutation detection, analysis of samples collected
closer to the time of gel use and seroconversion, and examina-
tion of HIV in the vaginal compartment afforded a more rigor-
ous assessment of both drug resistance transmission and
emergence in this tenofovir vaginal gel trial.
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MATERIALS AND METHODS
CAPRISA 004 Population and Sampling
The CAPRISA 004 study (ClinicalTrials.gov identifier
NCT00441298) enrolled 899 sexually active women from
urban and rural sites, who were aged 18–40 years and were
not pregnant, and randomly assigned them equally to a 1%
tenofovir hydroxyethycellulose gel arm or a hydroxyethycellu-
lose placebo gel arm. Subtype C HIV seroconversion occurred
in 38 of 422 (9%) women in the tenofovir gel arm and in 60 of
421 (14%) in the placebo arm.
In the current study, we evaluated all available plasma and
vaginal swab samples obtained closest to the estimated time of
seroconversion. For plasma virus, PCR amplicons from 65 sero-
converters, 28 (74%) from the tenofovir arm and 37 (62%) from
the placebo arm, were screened by means of sensitive resistance
testing at the Centers for Disease Control and Prevention. The
samples were masked as to the gel arms at the time of testing. Sev-
enty-five percent of the plasma specimens were collected within
30 days of estimated seroconversion (median, 14 days). Although
all earliest available samples were examined, the priority for test-
ing were women who reported applying gel within 30 days before
the estimated date of seroconversion. The University of KwaZulu-
Natal’s Biomedical Research Ethics committee approved the
study, and the institutional review board of the Centers for Dis-
ease Control and Prevention determined that participant consent
was provided for the HIV testing in this study.
Because vaginal lavage samples were unavailable for genital
HIV analysis, we evaluated cervicovaginal swab samples (Probe-
Tec; Becton-Dickinson) collected at the first scheduled study
visit after infection, when available, and stored in 0.5 mL of
phosphate-buffered saline (PBS) at −80°C. A total of 33 swab
samples from the tenofovir arm and 28 from the placebo arm
were tested. Before we elected to use the study swab samples
for HIV genotyping, we devised an extraction protocol and as-
sessed nucleic acid recovery using plasma samples of known
viral loads (see Supplementary Information).
Vaginal Virus Loads and Drug Concentrations
Vaginal viral loads were measured at the National Health Lab-
oratory Service Diagnostic Laboratory at Groote Schuur Hospi-
tal in South Africa, using a 1-mL fraction of 10 mL of PBS
cervicovaginal lavage in the Nuclisens Easyq HIV 1 kit, version
1.2 (detection limit, 50 copies/mL). Tenofovir concentrations
were quantified in 50 µL of directly aspirated cervicovaginal
fluid; the drug was extracted by using an acetonitrile protein
precipitation process (see Supplementary Information). We de-
fined the minimum appreciable drug concentration as 10 ng/mL.
HIV Nucleic Acid Amplification and Drug Resistance Testing
For real-time PCR drug resistance screening, virus template
from blood plasma was first generated as described elsewhere
[2]. For drug resistance screening from vaginal swab samples,
nucleic acids from the pooled PBS fractions (see Supplementary
Information) were extracted using the UltraSens viral RNA kit
(Qiagen) and eluted in a final 80-µL volume of buffer provided
with the kit. Five microliters of the extract was used in reverse-
transcription PCR amplification of the viral template, as
described elsewhere [3], except that High Fidelity PCR (Life
Technologies) was used in the current study.
The PCR-generated viral templates from blood and swab
samples were screened for the K65R (reaction is positive if the
difference in total virus copy versus mutation copy amplifica-
tion (ΔCT) was ≤8 cycles) and K70E (positive ΔCT, ≤7 cycles)
tenofovir resistance mutations using real-time PCR–based
(allele-specific) point mutation assays validated for subtype C
HIV, as described elsewhere ([4] and Supplementary Informa-
tion). Mutation-specific assay reactions that screened positive
were directly sequenced to verify that reading frames were intact
and mutation-positive underwent clonal analysis to verify mu-
tation frequency. In addition, the original reverse-transcription
PCR products were bulk genotyped to ascertain whether muta-
tions were at sufficiently high frequency to be identifiable by
population sequencing.
RESULTS
Plasma Drug Resistance and Tenofovir Exposure
Sensitive real-time PCR screening of 65 HIV seroconverter plas-
ma masked for gel arm found that only one participant, partic-
ipant 16, was positive for the K65R mutation (ΔCT, 3.7) in a
sample collected 3 weeks after infection. The remaining 64
specimens had no K65R reactivity within the cutoff. After
unmasking, it was disclosed the K65R-positive specimen was
from a participant assigned to the placebo gel arm (Tables 1
and 2; Supplementary Table 3). A subsequent bulk sequence
analysis revealed that she also had K103N and Y181C muta-
tions to nonnucleoside drugs not related to tenofovir. The re-
mainder of the placebo plasma samples had ΔCT values of
≥8.4 cycles (median, 9.9 cycles), which were similar to the
≥8.1 cycles (median, 9.8 cycles) obtained for the tenofovir
arm plasma samples.
Vaginal Tenofovir Concentrations
Tenofovir concentrations in cervicovaginal aspirates collected
around the time of swab sampling were available for 27 sero-
converters from the tenofovir arm. Seven aspirates (26%) had
drug concentrations >2 ng/mL (Table 2), ranging from <0.25
to 213 000 ng/mL (geometric mean, 4.12 ng/mL). Furthermore,
analysis of available preseroconversion aspirates from the
remaining 11 women who experienced seroconversion in the
tenofovir arm revealed only 3 women had detectable tenofovir
in any sample.
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Swab Sample Analysis
For the tenofovir resistance analysis of cervicovaginal swab
samples, we selected the earliest available postseroconversion
samples, thus the samples obtained closest to the time of antic-
ipated last gel use. Thirty-three swab samples from the tenofovir
arm (87% of seroconverters) and 28 from the placebo arm swab
(47% of seroconverters) were available for testing. The estimat-
ed durations of infection at the times of swab sample collection
ranged from 3 to 156 days (median, 19 days) for the tenofovir
arm and from 12 to 157 days (median, 19 days) for the placebo
arm seroconverters. Paired plasma and swab samples were
available for 38 participants, of which 23 were from the tenofo-
vir and 15 from the placebo arm. Testing the tenofovir arm swab
samples with the K65R assay identified no samples with reactiv-
ity below the cutoff (ΔCT ≥9.7 cycles; median, 12.8 cycles)
(Table 2). These results were similar to those obtained in testing
the placebo arm swab samples (ΔCT, ≥9.1 cycles; median, 13.1
cycles; Supplementary Table 3). No K70E was identified from
any swab specimens, which had ΔCT values of ≥9.7 cycles for
tenofovir arm and ≥10.0 cycles for placebo arm seroconverters.
DISCUSSION
In this sensitive screening study for HIV drug resistance in vag-
inal swab and plasma samples from seroconverting women who
participated in CAPRISA 004, we found no evidence of tenofo-
vir resistance associated with having been assigned tenofovir
vaginal gel. The cryopreserved swab specimens proved useful
for examining expression of tenofovir resistance in the genital
compartment where the topically applied tenofovir is primarily
concentrated. The tenofovir arm swab specimens produced
similar results to the placebo gel arm in the sensitive testing,
providing no indication of potential early resistance emergence
with tenofovir gel and no evidence of drug-resistant virus as a
cause of breakthrough infection.
Apart from the encouraging finding that the tenofovir gel afford-
ed significant protection when used, 9% of women assigned to te-
nofovir gel did experience seroconversion, and for a few, HIV-1
RNAwas detected in the vaginal compartment even when tenofo-
vir was present at appreciable concentrations. However, 74% of the
seroconverters tested in the tenofovir arm had insignificant vaginal
drug concentrations, even with self-reported gel use, revealing that
adherence to gel use was very low in these women and is likely to
explain the majority of seroconversions in the tenofovir gel group.
From the plasma and vaginal samples collected soon after in-
fection, we found the prevalence of transmitted resistance in the
study was low, with only 1 participant, a woman assigned to the
placebo arm, having evidence of infection with a drug-resistant
variant. The absence of tenofovir-associated mutations in the
tenofovir gel arm supports the conclusion that none of those
women became infected as a result of virus that was resistant
to tenofovir. The uncommon occurrence of transmitted K65R
is consistent with findings from surveillance of newly diagnosed
[5] and other evaluations of antiretoviral drug-naive infections
[6]. This bodes well for biomedical interventions that currently
use tenofovir; however, systematic monitoring for transmission
of this mutation would be timely as use of tenofovir in HIV
treatment expands. Oral prophylaxis trials [7–9] have also ex-
amined drug resistance and, as with CAPRISA 004, have iden-
tified no evidence of drug resistance emergence in persons who
seroconverted during the study period.
This drug resistance study had a few important limitations;
foremost, the apparent poor adherence to gel application in
the tenofovir seroconverters, as evidenced by the paucity of de-
tectable tenofovir in the vaginal aspirates, would have made
emergence of resistance unlikely. Another limitation to studying
drug resistance risk in this trial setting was the frequent moni-
toring of participants and immediate removal of study gel when
seroconversion was confirmed, thereby possibly not allowing
sufficient time for tenofovir resistance to emerge. Microbicide
implementation evaluations that involve less-frequent monitor-
ing could be better positioned to assess the potential for resis-
tance emergence with longer exposures to tenofovir in cases of
HIV acquisition. Nonetheless, some insight into the likelihood
of drug resistance emergence can be gleaned from nonhuman
primate studies. In 1 study, macaques exposed to repeated teno-
fovir gel applications for 10 weeks after simian-human immu-
nodeficiency virus breakthrough infections provided no
evidence of K65R when examined with sensitive assays [10],
suggesting that seroconversion while using tenofovir gel is not
likely to pose an immediate risk of drug resistance.
Table 1. Testing Summary for CAPRISA 004 Seroconverters
Testing Status or Outcome
Tenofovir
Gel (n = 38)
Placebo Gel
(n = 60)
Plasma tested, No. (%) 28 (74) 37 (62)
Swab samples tested, No. (%) 33 (87) 28 (47)
Swab samples amplifiable, No. (%) 21 (55) 21 (35)
Estimated duration of infection at
swab sample collection, median
(range), d
19 (3–156) 19 (12–157)
Used gel within last 30 d, % 45 43
Interval since application, range, d 0–20 0–16
Applicators used in last 30 days,
median (mean), No.
2 (3.8) 0 (2.9)
Vaginal tenofovir >2 ng/mL,
No. (%)
7/27 (26) . . .
Resistance detected below
cutoff, No. (%)
K65R (plasma) 0 1 (2.7)
K65R (swab samples) 0 0
K70E (plasma and swab
samples)
0 0
Abbreviation: CAPRISA 004, Centre for the AIDS Programme of Research in
South Africa 004.
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Swab Sample ΔCT, Cycles
K65Rd K70Ee K65Rd K70Ee
1f 37 Yes 22 500 9.0 12.6 . . . . . . . . . . . .
99 No 16 500 . . . . . . . . . <0.25 12.8 >25
2f 21 Yes 1000 11.2 12.9 . . . . . . . . . . . .
121 No <500 . . . . . . . . . <0.25 NA NA
3 21 Yes 6500 12.3 13.1 <50 6 18.2 >25
4 271 No 1500 9.1 12.7 . . . <0.25 . . . . . .
10 13 No 1000 22.0 12.5 <50 28 NA NA
13 96 No 1500 11.6 14.1 . . . . . . NA NA
14 14 Yes 6000 9.5 11.7 . . . <0.25 14.0 9.7
15f 34 Yes 10 000 9.8 11.4 . . . . . . . . . . . .
−29g Yes 10 000 . . . . . . . . . 78 NA NA
18 15 Yes 13 000 9.3 11.5 . . . 745 . . . . . .
20f 23 Yes 22 000 9.4 >25 . . . . . . . . . . . .
114 No 7000 . . . . . . . . . . . . NA NA
23 14 Yes 109 000 12.3 9.4 51 000 206 13.4 19.9
26 35 No 199 500 9.6 10.7 100 <0.25 NA NA
27 14 Yes 179 500 13.1 11.4 . . . <0.25 15.1 >25
30 58 Yes 4 433 000 8.5 10.8 . . . <0.25 NAh 10.8
31 14 Yes 88 500 9.6 14.4 . . . <0.25 11.7 >25
32f 21 Yes 15 000 8.1 11.8 . . . . . . . . . . . .
115 No 26 500 . . . . . . . . . <0.25 NA NA
34 20 Yes 52 500 8.9 10.4 . . . . . . 11.2 >25
35 13 Yes 220 500 10.4 10.0 700 213 103 10.1 >25
36 14 Yes 258 000 11.3 11.5 300 <0.25 11.5 14.0
40 141 No 305 000 11.7 11.7 . . . <0.25 11.6 15.7
42 15 Yes 534 000 9.9 20.3 2000 <0.25 14.3 >25
44 14 No 246 000 8.2 12.2 54 000 <0.25 9.7 >25
45f 52 No 130 000 13.0 >25 . . . . . . . . . . . .
3 No 330 000 . . . . . . . . . 6119 NA NA
46 18 Yes 124 000 8.1 10.0 . . . 18 707 . . . . . .
50 14 Yes 37 000 9.2 9.9 55 000 <0.25 >25 10.9
52 15 Yes 18 000 8.7 21.4 1800 <0.25 11.7 >25
55 14 Yes 500 10.1 12.0 . . . . . . . . . . . .
65 48 No 216 500 12.2 >25 . . . . . . 15.7 >25
66 121 No 30 000 . . . . . . . . . <0.25 >25 >25
67 14 Yes 48 500 . . . . . . . . . 12 NA NA
68 48 No 31 000 . . . . . . <50 <0.25 NA NA
69 14 Yes 500 . . . . . . <50 <0.25 NA NA
70 156 No 17 500 . . . . . . . . . <0.25 11.6 >25
71 135 No 111 000 . . . . . . 400 . . . NA NA
72 19 No 1 700 000 . . . . . . 7800 <0.25 11.5 >25
73 154 No 298 000 . . . . . . . . . <0.25 13.0 >25
74 123 No <500 . . . . . . . . . . . . NA NA
Abbreviations: ΔCT, difference in total virus copy amplification cycle and mutation-specific amplification cycle; CVL, cervicovaginal lavage; NA, not amplifiable;
VA, vaginal aspirate.
a Empty cells (. . .) indicate data unavailable.
b Gel used in past 30 days.
c Rounded to nearest 500 copies.
d Cutoff, 8.0 cycles.
e Cutoff, 7.0 cycle.
f Matched blood and swab samples were sampled from different days.
g Tested for evidence of early acute infection before seroconversion; participant seroconverted later, but no subsequent swab specimens were available.
h Insufficient template.
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In the current study, sensitive testing of both plasma and vag-
inal swab specimens produced no remarkable findings of teno-
fovir-induced drug resistance. However, a possible long-term
impact on subsequent tenofovir-containing antiretroviral treat-
ment regimens for women who seroconverted in the tenofovir
gel arm is being assessed in the CAPRISA 009 trial. In conclu-
sion, the findings from this study demonstrated no adverse drug
resistance outcome from the use of tenofovir vaginal gel and do
not raise concerns over continuing clinical evaluations of this
female-controlled product as an intervention against sexual ac-
quisition of HIV.
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